News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Deals
Nycomed Still Plans IPO
April 12, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
ZURICH—Closely held pharmaceutical company Nycomed SCA Monday said it still plans to launch an initial public offering despite a U.S. advisory panel voting not to recommend its lung drug Daxas.
Twitter
LinkedIn
Facebook
Email
Print
IPO
Europe
MORE ON THIS TOPIC
Artificial intelligence
Genentech makes $1.5B+ deal with AI heavyweight Earendil for cancer bispecifics
September 25, 2026
·
2 min read
·
Tristan Manalac
Deals
Roche inks up to $2B deal with Atavistik for new cardiometabolic drugs
September 24, 2026
·
2 min read
·
Gabrielle Masson
China
Lilly sets aside up to $3.25B to tackle critical unmet need targets with InnoCare
September 24, 2026
·
1 min read
·
Tristan Manalac
Job Trends
Growth mode: 3 biotechs that are staffing up after series B raises
September 24, 2026
·
3 min read
·
Angela Gabriel
